The 18,000-sq-ft facility will support the expansion of immunogenicity testing and target binding technologies.
ProImmune Ltd has opened its new global headquarters at Oasis Park in Oxford, UK, marking an expansion of the company’s operational capacity for life science reagents and services.
The new 18,000-sq-ft facility is part of ProImmune’s recent acquisition of the 70,000-sq-ft Oasis Park business and light industrial complex. The state-of-the-art laboratories will enable the company to accelerate development of its REVEAL Immunogenicity System and Ankyron target binding technologies.
The REVEAL system provides assay services designed to help researchers understand immune responses to vaccines and therapeutic products. The company’s Ankyron platform offers small, recombinant target binding ankyrin repeat proteins developed as an alternative to custom antibodies, featuring high specificity, sensitivity, and reproducibility.
“Our new global headquarters at Oasis Park, Oxford, are a reflection of ProImmune’s commitment to scientific excellence in immunology and global one-health biology,” says Dr Nikolai Schwabe, chief executive officer of ProImmune, in a release. “The investment into the park, and into our new flexible laboratory and office facilities, strengthens our ability to deliver world-class products and services, supporting our partners to develop safer and more effective therapies for patients around the world.”
Located within Oxford’s bioscience and innovation ecosystem, Oasis Park already houses six existing tenants. The facility expansion represents ProImmune’s investment in infrastructure to serve its global client base in the clinical laboratory and life sciences markets.
Ankyrons are designed to overcome challenges in antibody research by providing a cost-effective alternative to generating custom antibodies. The technology aims to address issues related to specificity, sensitivity and reproducibility that researchers may encounter with traditional antibody-based approaches.
The new headquarters will support ProImmune’s continued development of immunology tools and services for the global research community.
Photo caption: ProImmune’s new headquarters in Oxford, UK
Photo credit: ProImmune
